GEMBIN

This brand name is authorized in Nigeria. It is also authorized in Estonia, Lithuania.

Active ingredients

The drug GEMBIN contains one active pharmaceutical ingredient (API):

1	Gemcitabine UNII U347PV74IL - GEMCITABINE HYDROCHLORIDE
	Gemcitabine (dFdC), which is a pyrimidine antimetabolite, is metabolised intracellularly by nucleoside kinase to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect of gemcitabine is due to inhibition of DNA synthesis by two mechanisms of action by dFdCDP and dFdCTP.
	Read more about Gemcitabine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-4538	Powder for injection	Gembin 1000 Injection INJ_PWD 1 g 1 x 1's (in vial)	Lyophilized powder for solution for injection in vial. A white to off white lyophilized mass	31/07/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BC05	Gemcitabine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues
Discover more medicines within L01BC05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1393039, 1393040, 1393051
LT	Valstybinė vaistų kontrolės tarnyba	1035261, 1035262, 1035263
NG	Registered Drug Product Database	B4-4538